Foldax
- Company typePrivate
- Founded2019
- HeadquartersSalt Lake City, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Foldax firmographics
Firmographics- Name
- Foldax
- Legal name
- Foldax, Inc.
- Website
- https://foldax.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Foldax industry classification
Industry- Product category
- Heart Valve Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)
- akta.pro secondary industry
- Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)
Keywords
Where Foldax is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Foldax business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Heart Valve Product Sales: Revenue generated from the sale of TRIA surgical heart valves to hospitals and healthcare providers in approved markets such as India.
- LifePolymer™ Licensing: Foldax is actively licensing its LifePolymer™ portfolio for applications beyond heart valves, including medical devices (insulin pumps, catheters, drug delivery) and industrial applications (electronics, antifouling coatings).
- Patient Registry Data Services: Real-world data collected through the TRIA Patient Registry used for clinical studies, regulatory reporting, and innovation advancement.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Foldax product offering
Product offeringCore offering
Foldax develops and manufactures the TRIA heart valve platform, a family of surgical and transcatheter polymer heart valves made from its proprietary LifePolymer™ biopolymer and produced through robotic manufacturing. The platform targets aortic, mitral, and tricuspid valve positions and is designed to deliver lifetime durability without lifelong anticoagulation, addressing the long-standing tradeoffs of tissue and mechanical valve replacements. The company also licenses its LifePolymer™ material for broader medical device and industrial applications.
Product overview
Foldax develops the TRIA heart valve platform, which includes surgical mitral and aortic valves, as well as transcatheter (TAVR) versions. All TRIA valves utilize the proprietary LifePolymer biopolymer material and are manufactured using robotic automation. The mitral valve has received commercial approval in India while the aortic and transcatheter versions remain in clinical development in the United States. The platform is designed to address limitations of traditional tissue and mechanical valves by offering durability without the need for lifelong anticoagulation.
Differentiator
Problem solved
Functional benefit
Brands
- TRIA: TRIA heart valve platform - surgical and transcatheter polymer heart valves including TRIA Mitral Valve and TRIA Aortic Valve, designed for lifetime durability using LifePolymer material.
- TRIA™ Mitral Valve
- LifePolymer™
Products and services
- TRIA Mitral Valve A surgical heart valve replacement for mitral valve disease made with proprietary LifePolymer™ material; approved for commercial use in India by CDSCO and limited to investigational use in the United States.
- TRIA Aortic Valve A surgical heart valve replacement for aortic valve disease utilizing LifePolymer™ biopolymer material; currently in clinical development in the United States under FDA Early Feasibility Study.
- TRIA Transcatheter (TAVR) Valve A transcatheter aortic valve replacement device featuring a self-expanding nitinol frame with supra-annular leaflets made from LifePolymer™; under development.
- LifePolymer™ Material (Licensing) A proprietary synthetic polymer material developed specifically for heart valve applications and being licensed to medical device and industrial partners for use in insulin pumps, catheters, drug delivery systems, electronics, and antifouling coatings.
Quantifiable outcome
- >50% reduction in mean gradient (9.7 mmHg to 4.5 mmHg) and >90% increase in effective orifice area (0.9 cm² to 1.5 cm²) - highest reported in similar surgical mitral valve studies
- +4 more outcomes
Companies that use Foldax
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Foldax technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Foldax partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered regional, core and clinical trial site.
- Dolphin Life Science India LLPregionalManufacturing agreement signed February 27, 2024 for local production capabilities in India supporting commercial launch of TRIA Mitral Valve.
- CSIRO (Commonwealth Scientific and Industrial Research Organisation)coreFoldax completed outright acquisition of the LifePolymer patent portfolio from CSIRO in 2023. CSIRO developed LifePolymer to Foldax specifications with over three decades of R&D experience in designing polyurethanes for medical applications. Dr. Thilak Gunatillake was key scientist.
- Beaumont Hospital, Royal Oak, Michiganclinical trial siteFirst-in-human implant of TRIA heart valve performed July 30, 2019 under FDA Early Feasibility Study. Dr. Marc Sakwa, Chief of Cardiovascular Surgery, led the procedure.
- Columbia University Medical Centerclinical trial siteDr. Isaac George serves as Surgical Director of the Heart Valve Center and Principal Investigator. Key opinion leader site for TRIA valve clinical program.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Foldax competitors and assessment
Company assessmentBroad incumbents
- Edwards Lifesciences: Global leader in structural heart with the Sapien TAVR platform and surgical heart valve portfolio. Directly comparable as the dominant incumbent in transcatheter and surgical heart valves; Foldax's leadership team is largely ex-Edwards, and TRIA is positioned as an alternative to Edwards' tissue and mechanical valves.
- Medtronic: Markets the Evolut transcatheter aortic valve platform and broader cardiac surgery portfolio. Direct competitor in transcatheter and surgical aortic valve replacement, with vastly larger clinical evidence base and global salesforce.
- Abbott: Competes in structural heart through its Navitor and Portico TAVR systems and the Tendyne transcatheter mitral valve. Comparable as a broad incumbent with overlapping transcatheter and surgical valve products targeting the same cardiac surgeon and interventional cardiologist customers.
- Boston Scientific: Markets the ACURATE neo2 TAVR platform and broader structural heart portfolio (including acquired mitral repair technologies). Comparable as a diversified incumbent competing in transcatheter aortic valve replacement with similar hospital sales motion.
Direct peers
- Artivion (formerly CryoLife): Specializes in preserved tissue heart valves (e.g., On-X mechanical valve, CryoValve) used in surgical aortic and mitral replacement. Comparable as a focused surgical heart valve specialist competing in the same replacement market as TRIA surgical mitral and aortic valves.
- LivaNova: Manufactures mechanical heart valves and cardiac surgery products. Directly comparable as a focused surgical heart valve competitor, particularly relevant since TRIA's value proposition is to displace mechanical valves by eliminating anticoagulation requirements.
Emerging players
- JenaValve Technology: Early-commercialization-stage transcatheter aortic valve company focused on aortic regurgitation indication. Comparable as a smaller structural-heart specialist targeting surgical and interventional cardiologists with a novel valve design, though JenaValve remains pre-commercial.
- 4C Medical Technologies: Develops transcatheter mitral valve technologies (AltaValve). Comparable as an emerging structural-heart company focused specifically on the mitral indication — the same primary indication where Foldax has its first commercial approval — and similarly targeting patients underserved by current surgical mitral options.
- Ancora Heart: Developer of transcatheter mitral repair technologies (AccuCinch). Comparable as a small private structural-heart company pursuing the mitral valve disease market with a novel interventional approach, sharing a similar emerging-player profile and customer base with Foldax.
- Xeltis: Clinical-stage company developing bioabsorbable polymer-based cardiovascular prostheses including heart valves. Comparable as a materials-driven structural-heart innovator using novel polymer chemistry — closely aligned with Foldax's LifePolymer™ approach — but pursuing restorative rather than purely synthetic leaflet technology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Foldax social profiles
Digital presenceFoldax financial estimates
Financial estimateRevenue estimate
Valuation estimate
Foldax leadership team
Management profileNumber of profiles
Profiles10 records
Foldax funding detail
Funding detailFunding overview
Funding rounds8 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Foldax M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Foldax
What does Foldax do?
Foldax develops and manufactures the TRIA heart valve platform, a family of surgical and transcatheter polymer heart valves made from its proprietary LifePolymer™ biopolymer and produced through robotic manufacturing. The platform targets aortic, mitral, and tricuspid valve positions and is designed to deliver lifetime durability without lifelong anticoagulation, addressing the long-standing tradeoffs of tissue and mechanical valve replacements. The company also licenses its LifePolymer™ material for broader medical device and industrial applications.
Is Foldax a public or private company?
Foldax is a private company. It is classified as venture growth investor backed and is currently operating.
When was Foldax founded?
Foldax was founded in 2019. It employs 11 to 50 people.
Where is Foldax based?
Foldax is headquartered in Salt Lake City, United States, in the North America region.
How does Foldax make money?
Three revenue lines are on record. Heart Valve Product Sales are the primary driver. The others are lifePolymer™ Licensing and patient Registry Data Services.
Who are Foldax's main competitors?
Broad incumbents on record are Edwards Lifesciences, Medtronic, Abbott and Boston Scientific. Direct peers are Artivion (formerly CryoLife) and LivaNova. Emerging players are JenaValve Technology, 4C Medical Technologies, Ancora Heart and Xeltis.
Does Foldax have an API?
No public API is recorded for Foldax.
What industry is Foldax in?
Foldax's product category is Heart Valve Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAH, Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts). Its NAICS code is 339113 and its SIC code is 3841.